About Teletype
Join
S
Sheetal
@sheetal
May 14, 2020

Pharmacovigilance Market Global Trends, Size, Shares and Growth Analysis by 2020-2027

According to the Acumen Research and Consulting, the global Pharmacovigilance market is expected to reach at US$ 10.6 billion by 2026, along with the projected CAGR of 12.8 % from 2020-2026.

The published report global Pharmacovigilance market provides a holistic overview of the current market covering the current trends. The provided quantitative and qualitative data is based on the deeper analysis of the historical data and the current market situation that helps to provide an overview of the forecasted period.

Get Sample PDF @ https://www.acumenresearchandconsulting.com/request-sample/1331

The global Pharmacovigilance market report provides deeper insights on the factors driving the global market along with the factors that are responsible to hamper the growth. In addition, the report provides the opportunities in the global Pharmacovigilance market that would help the competitors to increase the profit share.

The global Pharmacovigilance market report provides the quantitative information of the target segment that is covered in the report along with the regional data comparison.

The report provides an overview value chain analysis, Porters Five analysis, and cost structure analysis gives an idea of the industrial outlook. The global Pharmacovigilance market report covers the data of the major geographical regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the report also covers the country cross section providing deeper insights of the particular region.

The published global Pharmacovigilance market report provides information about the major players operating in the target market. The company profile section provides important information about the major players, along with the financial overview, product segment revenue, the geographical presence of the company. It also provides information related to business development activities by the players such as merger & acquisition, partnerships and agreements.

The global Pharmacovigilance market report also covers the products information that is offered by the particular players along with the specification. In addition, the player positioning based on their business strengths and product offerings which provides the competitive outlook of the industry.

Market participants

Clinquest Group, IBM Corporation, ArisGlobal, ICON plc. Accenture, Clinquest Group B.V., Cognizant, Laboratory Corporation of America Holdings. TAKE Solutions Ltd., PAREXEL International Corporation, BioClinica, Wipro Ltd. and United BioSource Corporation, Capgemini, iMEDGlobal, Foresight Group International AG., among others

Market segmentation

Global Pharmacovigilance Market, by Clinical Trial Phase

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Global Pharmacovigilance Market, by Service

  • In-house
  • Contract Outsourcing

Global Pharmacovigilance Market, by Type

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Global Pharmacovigilance Market, by End Use

  • Hospitals
  • Research Organizations
  • Industrial

Global Pharmacovigilance Market, by Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Table of content

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Pharmacovigilance
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Pharmacovigilance Market By Clinical Trial Phase
1.2.2.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Clinical Trial Phase (2015-2026)
1.2.2.2. Global Pharmacovigilance Market Revenue Share By Clinical Trial Phase in 2017
1.2.2.3. Pre-clinical
1.2.2.4. Phase I
1.2.2.5. Phase II
1.2.2.6. Phase III
1.2.2.7. Phase IV
1.2.3. Pharmacovigilance Market By Service
1.2.3.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Service (2015-2026)
1.2.3.2. Global Pharmacovigilance Market Revenue Share By Service in 2017
1.2.3.3. In-house
1.2.3.4. Contract Outsourcing
1.2.4. Pharmacovigilance Market By Type
1.2.4.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.4.2. Global Pharmacovigilance Market Revenue Share By Type in 2017
1.2.4.3. Spontaneous Reporting
1.2.4.4. Intensified ADR Reporting
1.2.4.5. Targeted Spontaneous Reporting
1.2.4.6. Cohort Event Monitoring
1.2.4.7. EHR Mining
1.2.5. Pharmacovigilance Market By End Use
1.2.5.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.5.2. Global Pharmacovigilance Market Revenue Share By End Use in 2017
1.2.5.3. Hospitals
1.2.5.4. Research Organizations
1.2.5.5. Industrial
1.2.6. Pharmacovigilance Market by Geography
1.2.6.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Pharmacovigilance Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Pharmacovigilance Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Pharmacovigilance Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Pharmacovigilance Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Pharmacovigilance Major Manufacturers in 2017

CHAPTER 4. Pharmacovigilance Market By Clinical Trial Phase

4.1. Global Pharmacovigilance Revenue By Clinical Trial Phase
4.2. Pre-clinical
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Phase I
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Phase II
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Phase III
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Phase IV
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. Pharmacovigilance Market By Service

5.1. Global Pharmacovigilance Revenue By Service
5.2. In-house
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Contract Outsourcing
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. Pharmacovigilance Market By Type

6.1. Global Pharmacovigilance Revenue By Type
6.2. Spontaneous Reporting
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Intensified ADR Reporting
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Targeted Spontaneous Reporting
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Cohort Event Monitoring
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.6. EHR Mining
6.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. Pharmacovigilance Market By End Use

7.1. Global Pharmacovigilance Revenue By End Use
7.2. Hospitals
7.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.3. Research Organizations
7.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.4. Industrial
7.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 8. North America Pharmacovigilance Market By Country

8.1. North America Pharmacovigilance Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. North America Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Pharmacovigilance Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.3.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.4.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.5.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)

CHAPTER 9. Europe Pharmacovigilance Market By Country

9.1. Europe Pharmacovigilance Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Europe Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.3.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.4.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.5.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.6.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.7.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)

CHAPTER 10. Asia-Pacific Pharmacovigilance Market By Country

10.1. Asia-Pacific Pharmacovigilance Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Asia-Pacific Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.3.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.4.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.5.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
10.6.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
10.6.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.6.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
10.7.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
10.7.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.7.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
10.8.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
10.8.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.8.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)

CHAPTER 11. Latin America Pharmacovigilance Market By Country

11.1. Latin America Pharmacovigilance Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Latin America Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.3.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.4.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.5.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)

CHAPTER 12. Middle East Pharmacovigilance Market By Country

12.1. Middle East Pharmacovigilance Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Middle East Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
12.3.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.3.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
12.4.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.4.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
12.5.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.5.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)

CHAPTER 13. Africa Pharmacovigilance Market By Country

13.1. Africa Pharmacovigilance Market Revenue and Growth Rate, 2015 – 2026 ($Million)
13.2. Africa Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
13.3.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
13.3.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.3.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
13.4.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
13.4.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.4.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 – 2026 ($Million)
13.5.2. Market Revenue and Forecast By Service, 2015 – 2026 ($Million)
13.5.3. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.5.4. Market Revenue and Forecast By End Use, 2015 – 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Clinquest Group
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. IBM Corporation
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. ArisGlobal
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. ICON plc.
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Accenture
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Clinquest Group B.V.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Cognizant
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Laboratory Corporation
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. TAKE Solutions Ltd.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. PAREXEL International Corporation
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
14.11. BioClinica
14.11.1. Company Snapshot
14.11.2. Overview
14.11.3. Financial Overview
14.11.4. Product Portfolio
14.11.5. Key Developments
14.11.6. Strategies
14.12. Wipro Ltd.
14.12.1. Company Snapshot
14.12.2. Overview
14.12.3. Financial Overview
14.12.4. Product Portfolio
14.12.5. Key Developments
14.12.6. Strategies
14.13. United BioSource Corporation
14.13.1. Company Snapshot
14.13.2. Overview
14.13.3. Financial Overview
14.13.4. Product Portfolio
14.13.5. Key Developments
14.13.6. Strategies
14.14. Capgemini
14.14.1. Company Snapshot
14.14.2. Overview
14.14.3. Financial Overview
14.14.4. Product Portfolio
14.14.5. Key Developments
14.14.6. Strategies
14.15. iMEDGlobal
14.15.1. Company Snapshot
14.15.2. Overview
14.15.3. Financial Overview
14.15.4. Product Portfolio
14.15.5. Key Developments
14.15.6. Strategies
14.16. Foresight Group International AG.
14.16.1. Company Snapshot
14.16.2. Overview
14.16.3. Financial Overview
14.16.4. Product Portfolio
14.16.5. Key Developments
14.16.6. Strategies
14.17. Others
14.17.1. Company Snapshot
14.17.2. Overview
14.17.3. Financial Overview
14.17.4. Product Portfolio
14.17.5. Key Developments
14.17.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

Buy this premium report @ https://www.acumenresearchandconsulting.com/buy-now/0/1331

Contact us:

Sheetal k

Email: [email protected]

Phone: +14079154157 | +14089009135

Website: https://www.acumenresearchandconsulting.com

Acumen Research and Consulting (ARC)
May 14, 2020, 07:20
0 reactions
0 views